{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T01:54:09Z","timestamp":1767837249217,"version":"3.49.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,9,1]]},"DOI":"10.1093\/humrep\/dei074","type":"journal-article","created":{"date-parts":[[2005,5,13]],"date-time":"2005-05-13T00:24:34Z","timestamp":1115943874000},"page":"2421-2425","source":"Crossref","is-referenced-by-count":50,"title":["Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome"],"prefix":"10.1093","volume":"20","author":[{"given":"G.","family":"Ragni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Vegetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Riccaboni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Engl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Brigante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.G.","family":"Crosignani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,5,12]]},"reference":[{"key":"key\n\t\t\t\t20171011131623_R1","doi-asserted-by":"crossref","unstructured":"Albano C, Felberbaum RE, Smitz J, Riethm\u00fcller-Winzen H, Engel J, Diedrich K and Devroey P (2000) Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod15, 526\u2013531.","DOI":"10.1093\/humrep\/15.3.526"},{"key":"key\n\t\t\t\t20171011131623_R2","doi-asserted-by":"crossref","unstructured":"Al-Inany H and Aboulghar M (2002) GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod17, 874\u2013885.","DOI":"10.1093\/humrep\/17.4.874"},{"key":"key\n\t\t\t\t20171011131623_R3","doi-asserted-by":"crossref","unstructured":"Asch RH, Li HP, Balamceda JP, Weckstein LN and Stone SC (1991) Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Hum Reprod6, 1395\u20131399.","DOI":"10.1093\/oxfordjournals.humrep.a137276"},{"key":"key\n\t\t\t\t20171011131623_R4","doi-asserted-by":"crossref","unstructured":"Crooke AC (1970) Induction of ovulation with gonadotrophins. Br Med Bull26, 17\u201321.","DOI":"10.1093\/oxfordjournals.bmb.a070736"},{"key":"key\n\t\t\t\t20171011131623_R5","doi-asserted-by":"crossref","unstructured":"Delvigne A and Rozenberg S (2002) Epidemiology and prevention of ovarian hypersstimulation syndrome (OHSS): a review. Hum Reprod Update8, 559\u2013577.","DOI":"10.1093\/humupd\/8.6.559"},{"key":"key\n\t\t\t\t20171011131623_R6","doi-asserted-by":"crossref","unstructured":"Delvigne A, Demoulin A, Smitz J, Donnez J, Koninckx P, Dhont M, Englert Y, Delbeke L, Darcis L, Gordts S et al. (1993) The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I: Clinical and biological features. Hum Reprod8, 1353\u20131360.","DOI":"10.1093\/oxfordjournals.humrep.a138260"},{"key":"key\n\t\t\t\t20171011131623_R7","doi-asserted-by":"crossref","unstructured":"Enskog A, Henriksson M, Unander M, Nilsson L and Brannstrom M (1999) Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril71, 808\u2013814.","DOI":"10.1016\/S0015-0282(99)00090-4"},{"key":"key\n\t\t\t\t20171011131623_R8","doi-asserted-by":"crossref","unstructured":"European-Middle East Orgalutran Study Group (2001) Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod16, 644\u2013651.","DOI":"10.1093\/humrep\/16.4.644"},{"key":"key\n\t\t\t\t20171011131623_R9","doi-asserted-by":"crossref","unstructured":"European Orgalutran Study Group (2000) Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Hum Reprod15, 1490\u20131498.","DOI":"10.1093\/humrep\/15.7.1490"},{"key":"key\n\t\t\t\t20171011131623_R10","doi-asserted-by":"crossref","unstructured":"Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ, Rinehart J, Rosenwaks Z, Scott RT Jr, Schoolcraft W et al. (2001) Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril75, 38\u201345.","DOI":"10.1016\/S0015-0282(00)01638-1"},{"key":"key\n\t\t\t\t20171011131623_R11","doi-asserted-by":"crossref","unstructured":"Forman RG, Frydman R, Egan D, Ross C and Barlow DH (1990) Severe ovarian hyperstimulation syndrome using agonist of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention. Fertil Steril53, 502\u2013509.","DOI":"10.1016\/S0015-0282(16)53348-2"},{"key":"key\n\t\t\t\t20171011131623_R12","doi-asserted-by":"crossref","unstructured":"Haning RV Jr, Austin CW, Carlson IH, Kuzma DL, Shapiro SS and Zweibel WJ (1983) Plasma estradiol is superior to ultrasound and urinary estriol glucuronide as a predictor of ovarian hyperstimulation during induction of ovulation with menotropins. Fertil Steril40, 31\u201336.","DOI":"10.1016\/S0015-0282(16)47173-6"},{"key":"key\n\t\t\t\t20171011131623_R13","doi-asserted-by":"crossref","unstructured":"Kulikowski M, Wolczynski S, Kuczynski W, Grochowski D and Szamatowicz M (1995) Use of GnRH analog for induction of the ovulatory surge of gonadotropins in patients at risk of the ovarian hyperstimulation syndrome. Gynecol Endocrinol9, 97\u2013102.","DOI":"10.3109\/09513599509160197"},{"key":"key\n\t\t\t\t20171011131623_R14","doi-asserted-by":"crossref","unstructured":"Ludwig M, Felberbaum RE, Devroey P, Albano C, Riethm\u00fcller-Winzen H, Sch\u00fcler A, Engel W and Diedrich K (2000) Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonists Cetrorelix (Cetrotide\u00ae) in controlled ovarian stimulation for assisted reproduction. Arch Gynecol Obstet264, 29\u201332.","DOI":"10.1007\/PL00007479"},{"key":"key\n\t\t\t\t20171011131623_R15","doi-asserted-by":"crossref","unstructured":"Ludwig M, Katalinic A and Diedrich K (2001) Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Arch Gynecol Obstet265, 175\u2013182.","DOI":"10.1007\/s00404-001-0267-2"},{"key":"key\n\t\t\t\t20171011131623_R16","doi-asserted-by":"crossref","unstructured":"MacDougall MJ, Tan SL and Jacobs HS (1992) In-vitro fertilization and the ovarian hyperstimulation syndrome. Hum Reprod7, 597\u2013600.","DOI":"10.1093\/oxfordjournals.humrep.a137702"},{"key":"key\n\t\t\t\t20171011131623_R17","unstructured":"Machin D, Campbell M, Fayers P and Pinol A (1997) Sample Size Tables for Clinical Studies. 2nd. Blackwell Science, Oxford, UK."},{"key":"key\n\t\t\t\t20171011131623_R18","doi-asserted-by":"crossref","unstructured":"Marthur RS, Akande AV, Keay SD, Hunt LP and Jenkins JM (2000) Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril73, 901\u2013907.","DOI":"10.1016\/S0015-0282(00)00492-1"},{"key":"key\n\t\t\t\t20171011131623_R19","doi-asserted-by":"crossref","unstructured":"Mordel N and Schenker JG (1993) Gonadotrophin-releasing hormone agonists and ovarian hyperstimulation syndrome in assisted reproduction. Hum Reprod8, 2009\u20132014.","DOI":"10.1093\/oxfordjournals.humrep.a137973"},{"key":"key\n\t\t\t\t20171011131623_R20","doi-asserted-by":"crossref","unstructured":"Navot D, Relou A, Birkenfels A, Rabinowitz R, Brzezinski A and Margalioth EJ (1988) Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol159, 210\u2013215.","DOI":"10.1016\/0002-9378(88)90523-6"},{"key":"key\n\t\t\t\t20171011131623_R21","doi-asserted-by":"crossref","unstructured":"Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L, Nicollet B, Zorn JR, Bouchard P and Frydman R (2000) Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril73, 314\u2013320.","DOI":"10.1016\/S0015-0282(99)00524-5"},{"key":"key\n\t\t\t\t20171011131623_R22","doi-asserted-by":"crossref","unstructured":"Penzias AS (2002) Luteal phase support. Fertil Steril77, 318\u2013323.","DOI":"10.1016\/S0015-0282(01)02961-2"},{"key":"key\n\t\t\t\t20171011131623_R23","unstructured":"Raga F, Casa\u00f1 EM, Dubon MD, Marti R, Bonilla-musoles F and Polan ML (2002) Modulation of vascular endothelial growth factor by GnRH analogues: potential use in clinical management of ovarian hyperstimulation syndrome. Abstract presented at the 18th Meeting of the European Society of Human Reproduction and Embryology. Hum Reprod17 (Suppl 1), 14 (abstract O-037)."},{"key":"key\n\t\t\t\t20171011131623_R24","doi-asserted-by":"crossref","unstructured":"Rizk B and Smitz J (1992) Ovarian hyperstimulation syndrome after superovulation using GnRH agonists for IVF and related procedures. Hum Reprod7, 320\u2013327.","DOI":"10.1093\/oxfordjournals.humrep.a137642"},{"key":"key\n\t\t\t\t20171011131623_R25","doi-asserted-by":"crossref","unstructured":"Segal S and Casper RF (1992) Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin for triggering follicular maturation in in vitro fertilization. Fertil Steril57, 1254\u20131258.","DOI":"10.1016\/S0015-0282(16)55083-3"},{"key":"key\n\t\t\t\t20171011131623_R26","doi-asserted-by":"crossref","unstructured":"Shalev E, Geslevich Y, Matilsky M and Ben-Ami M (1995) Induction of pre-ovulatory gonadotrophin surge with gonadotrophin-releasing hormone agonist compared to pre-ovulatory injection of human chorionic gonadotrophins for ovulation induction in intrauterine insemination treatment cycles. Hum Reprod10, 2244\u20132247.","DOI":"10.1093\/oxfordjournals.humrep.a136277"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/20\/9\/2421\/6953707\/dei074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T17:19:02Z","timestamp":1507742342000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/humrep\/article\/20\/9\/2421\/2356736\/Comparison-of-GnRH-agonists-and-antagonists-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,12]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2005,5,12]]},"published-print":{"date-parts":[[2005,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/dei074","relation":{},"ISSN":["1460-2350","0268-1161"],"issn-type":[{"value":"1460-2350","type":"electronic"},{"value":"0268-1161","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,9]]},"published":{"date-parts":[[2005,5,12]]}}}